Gilead Sciences (GILD) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($6.61 million) and the uptick to downtick ratio was 0.93. The transaction value on upticks was $84.39 million and on downticks, the transaction value was $91 million. In block trades, the transaction value of inflow done during uptick was $8.54 million. The transaction value of block trades during downticks was $10.28 million. The uptick to downtick block trade ratio was 0.83. The money flow was negative ($1.74 million), indicating the traders were booking profit on the price strength. Gilead Sciences (GILD) rose $0.38 at $86.63, during intraday Tuesday , a rise of 0.44% over the previous days close.
The company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.9% . Institutional Investors own 81.78% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -9.29%. In an insider trading activity,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 112,000 shares at $84.62 on July 5, 2016. The Insider selling transaction had a total value worth of $9,477,440. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Shares of Gilead Sciences Inc. rose by 3.27% in the last five trading days and 3.16% for the last 4 weeks. Gilead Sciences Inc. has dropped 10.41% during the last 3-month period . Year-to-Date the stock performance stands at -13.49%.
Gilead Sciences (NASDAQ:GILD): stock turned positive on Tuesday. Though the stock opened at $86.82, the bulls momentum made the stock top out at $87.31 level for the day. The stock recorded a low of $86.48 and closed the trading day at $86.63, in the green by 0.44%. The total traded volume for the day was 7,857,677. The stock had closed at $86.25 in the previous days trading.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.